We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Sanofi's dengue vaccine first to complete phase 3.
- Authors
Sinha, Gunjan
- Abstract
The article focuses on the completion of phase 3 trials of ChimeriVaxdengue, a recombinant DNA vaccine, developed by the pharmaceutical firm Sanofi Pasteur for the treatment of dengue. Topics include investment of 1.35 billion dollars by in development of the vaccine, spreading of dengue by the bite of an infected Aedes aegypti mosquito and the symptoms of dengue fever. It mentions the study of the higher rate of dengue infection in 2013 more than as estimated by the World Health Organization.
- Subjects
DNA vaccines; DENGUE; SANOFI Pasteur SA; WORLD Health Organization; AEDES aegypti; VACCINATION
- Publication
Nature Biotechnology, 2014, Vol 32, Issue 7, p605
- ISSN
1087-0156
- Publication type
Article
- DOI
10.1038/nbt0714-605a